Skip to main content
MIT Corporate Relations
MIT Corporate Relations
Search
×
Events
STEX25
Startups
opportunities
MIT ILP
Sign-In
Register Your Startup
Search
Search
×
STEX Home
Events
Corporates
Event Videos
Startups
STEX25
Featured
Videos
Startups
Search
News
opportunities
MIT ILP
User Menu and Search
Sign-In
Register Your Startup
Search
STEX Home
Toggle menu
Search
Sign-in
Register your startup
Events
Corporates
Event Videos
Startups
STEX25
Featured
Videos
Startups
Search
News
opportunities
MIT ILP
Back to search results
Stratagen Bio
STEX25
Active dates:
January 20, 2023 - January 20, 2023
STEX25
View Feature
STEX25 Participation:
January 20, 2023 - December 31, 2024
Company information
Contact
No Street Listed
Cambridge
,
MA
02139
United States
https://stratagenbio.com/
Empty Facebook link
https://www.linkedin.com/company/55051826
Empty YouTube link
http://twitter.com/stratagenbio
Keywords
Oxygen Sensing
,
Magnetic Resonance Imaging
,
Image-Guided Therapies
,
personalized medicine
Elevator Pitch
Elevator Pitch
Stratagen Bio is transforming MRI into a tool for quantitative biomarker assessment and objective clinical decision making.
Description
Description
Tumor hypoxia is characterized by extremely low levels of oxygen (<15.2 mmHg/2% O2). It occurs in fifty percent1 of all tumors and is a well-established negative prognostic indicator. Poor outcomes are seen in patients with hypoxic tumors in cancers including breast, cervical, head and neck, soft tissue sarcomas, pancreatic, and prostate. These patients suffer from higher relapse rates and lower survival rates than those with more well-oxygenated tumors. These poor outcomes are driven by resistance to treatment in hypoxic tumors. Beyond patients and clinicians, it is critical for companies developing new therapies targeting hypoxic tumors to properly identify patients for their treatments.
Technology Description
Technology Description
Our first product, the OxyTrack platform, is a proprietary tissue oxygen sensor, treatment guidance software, and AI-enabled oxygen data engine. Our platform enables clinicians to incorporate direct and absolute measurements of tissue oxygen in their treatment planning process which isn’t currently possible. Our OxyTrack platform can be used to personalize care and improve outcomes beyond cancer in applications including trauma, ischemic injuries, and vascular disorders. Our OxyTrack sensors are fiducial marker sized, provide an absolute and direct measurement of tissue oxygen, and are read using commercial MRI sequences and scanners. The sensors are made completely of medical-grade silicone and are placed using minimally invasive methods that are standard of care for the placement of fiducial markers and brachytherapy seeds.